Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

Mechanisms of action of EGFR tyrosine kinase receptor incorporated in extracellular vesicles

EGFR and some of the cognate ligands extensively traffic in extracellular vesicles (EVs) from different biogenesis pathways. EGFR belongs to a family of four homologous tyrosine kinase receptors (TKRs). This family are one of the major drivers of cancer and is involved in several of the most frequen...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Zanetti-Domingues, LC, Martin-Fernandez, ML, Huber, V
التنسيق:	Journal article
اللغة:	English
منشور في:	MDPI 2020

مواد مشابهة

Mechanisms of Action of EGFR Tyrosine Kinase Receptor Incorporated in Extracellular Vesicles
حسب: Laura C. Zanetti-Domingues, وآخرون
منشور في: (2020-11-01)

Cooperation and interplay between EGFR signalling and extracellular vesicle biogenesis in cancer
حسب: Zanetti-Domingues, LC, وآخرون
منشور في: (2020)

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer
حسب: Laura C. Zanetti-Domingues, وآخرون
منشور في: (2020-12-01)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
حسب: Xu H, وآخرون
منشور في: (2019-07-01)

Extracellular Vesicles As Mediators of Resistance to EGFR-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Preclinical Models
حسب: M. Pérez-Capó, وآخرون
منشور في: (2023-11-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
حسب: Lihua Huang, وآخرون
منشور في: (2015-09-01)

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
حسب: Lu Yang, وآخرون
منشور في: (2022-06-01)

Radiation-Induced Tumor-Derived Extracellular Vesicles Combined with Tyrosine Kinase Inhibitors: An Effective and Safe Therapeutic Approach for Lung Adenocarcinoma with EGFR19Del
حسب: Yao Li, وآخرون
منشور في: (2024-12-01)

HIV Activates the Tyrosine Kinase Hck to Secrete ADAM Protease-Containing Extracellular Vesicles
حسب: J.-H. Lee, وآخرون
منشور في: (2018-02-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and IGF-1R
حسب: Cornelius Hempel, وآخرون
منشور في: (2017-01-01)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
حسب: Igor Makhlin, وآخرون
منشور في: (2019-11-01)

An extracellular receptor tyrosine kinase motif orchestrating intracellular STAT activation
حسب: Katri Vaparanta, وآخرون
منشور في: (2022-11-01)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
حسب: Tasia Amelia, وآخرون
منشور في: (2022-01-01)

Extracellular vesicle-associated tyrosine kinase-like orphan receptors ROR1 and ROR2 promote breast cancer progression
حسب: Barnabas Irmer, وآخرون
منشور في: (2023-07-01)

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
حسب: Aude I. Ségaliny, وآخرون
منشور في: (2015-03-01)

Editorial: Discovery of EGFR tyrosine kinase inhibitors for cancer treatment
حسب: Panupong Mahalapbutr, وآخرون
منشور في: (2024-02-01)

Extracellular Vesicles Act as Nano-Transporters of Tyrosine Kinase Inhibitors to Revert Iodine Avidity in Thyroid Cancer
حسب: Ramya Lakshmi Rajendran, وآخرون
منشور في: (2021-02-01)

Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors
حسب: Shannon S. Zhang, MD, وآخرون
منشور في: (2022-08-01)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with <i>EGFR</i> Mutations
حسب: Kenichi Suda, وآخرون
منشور في: (2021-06-01)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
حسب: Xingyuan Li, وآخرون
منشور في: (2023-10-01)

Mechanisms of receptor tyrosine kinase activation in cancer
حسب: Zhenfang Du, وآخرون
منشور في: (2018-02-01)

Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
حسب: Kinlin L Chao, وآخرون
منشور في: (2012-01-01)

Action Mechanisms of Small Extracellular Vesicles in Inflammaging
حسب: Rocío Mato-Basalo, وآخرون
منشور في: (2022-04-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
حسب: Marcin Skrzypski, وآخرون
منشور في: (2017-09-01)

Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
حسب: Keigo Kobayashi
منشور في: (2023-12-01)

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
حسب: Daniel B Costa, وآخرون
منشور في: (2007-10-01)

EGFR tyrosine kinase activity and Rab GTPases coordinate EGFR trafficking to regulate macrophage activation in sepsis
حسب: Xuedi Zhang, وآخرون
منشور في: (2022-11-01)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
حسب: Zhe Zhang, وآخرون
منشور في: (2019-11-01)

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance
حسب: Tim Fischer, وآخرون
منشور في: (2018-01-01)

A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
حسب: K. K. Laktionov, وآخرون
منشور في: (2019-06-01)

miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors
حسب: Tatsuki Shibuta, وآخرون
منشور في: (2022-06-01)

Proteolytic Cleavage of Receptor Tyrosine Kinases
حسب: Hao Huang
منشور في: (2021-04-01)

Receptor Tyrosine Kinases — Expanding Horizons
حسب: Sassan Hafizi
منشور في: (2014-06-01)

Extracellular phosphorylation of a receptor tyrosine kinase controls synaptic localization of NMDA receptors and regulates pathological pain.
حسب: Kenji Hanamura, وآخرون
منشور في: (2017-07-01)

Mechanisms of Activation of Receptor Tyrosine Kinases: Monomers or Dimers
حسب: Ichiro N. Maruyama
منشور في: (2014-04-01)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
حسب: Jihene Elloumi-Mseddi, وآخرون
منشور في: (2013-01-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
حسب: Nathaniel J. Myall, MD, وآخرون
منشور في: (2025-02-01)

ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFR
حسب: D. D. SAKAEVA
منشور في: (2017-06-01)

Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
حسب: Soomin Kim, وآخرون
منشور في: (2025-02-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
حسب: Wu Z, وآخرون
منشور في: (2019-10-01)